| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03389438 Details | 2021-12-01 Interventional | 2 | 6 | Immunomodulatin… Carcinoma, Tran… Urinary Bladder… Urinary Bladder… | Shortage of funds. - | |||
| NCT01134601 Details | 2021-12-01 Interventional | 1 | 1 | Capecitabine Adenocarcinoma Rectal Neoplasm… Non-Metastatic … | As per Cancer Therapy Evaluation Program (CTEP), this protocol has only enrolled one
participant and it is unlikely that the study will be able to be completed successfully. CTEP
slated the protocol to be administratively closed. - | |||
| NCT03550313 2020-005039-59 Details | 2021-11-30 Interventional | 2 | 565 | Heptavalent Pne… Pneumococcal In… | Study vaccinations and blood draws were halted due to adequacy of a smaller dataset and study
feasibility issues. It was not based on any safety concerns. - | |||
| NCT02930941 Details | 2021-11-30 Interventional | 4 | 35 | Tranexamic Acid Emergencies Epistaxis | Terminate due to slow enrollment rate. Coronavirus Disease 2019 (COVID-19) pandemic significantly impacted the ability to enroll patients; early termination leading to a small number of patients; single-center study; | |||
| NCT04637555 2020-003906-29 Details | 2021-11-26 Interventional | 3 | 0 | Sacubitril and … Valsartan Infarction Myocardial Infa… Post Myocardial… | CLCZ696G2301E1 extension study did not start as the core study (CLCZ696G2301) did not meet the
primary endpoint. - | |||
| NCT02627677 2015-001318-92 Details | 2021-11-26 Interventional | 3 | 44 | Nilotinib Ponatinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Chronic Phase C… | The study was stopped due to operational feasibility and not due to any safety concerns This study was terminated due to operational feasibility and not due to any safety concerns. | |||
| NCT05133635 Details | 2021-11-24 Interventional | 4 | 0 | Methylprednisol… Methylprednisol… Methylprednisol… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… COVID-19 Cytokine Releas… COVID-19 Virus … Corticosteroid Cytokine Storm Tocilizumab | A recent study suggested a new corticosteroid regime for intensive care unit patients. - | |||
| NCT02045901 Details | 2021-11-23 Interventional | 4 | 131 | Dicyclomine, do… Morning Sicknes… Nausea Vomiting | - - | |||
| NCT01324141 Details | 2021-11-23 Interventional | 1 | 6 | Fluorouracil Mitomycin Mitomycins Tempol Anus Neoplasms Dermatitis Anal Cancer | Slow, insufficient accrual and failure to meet endpoints. - | |||
| NCT00594230 Details | 2021-11-22 Interventional | 2 | 26 | Panobinostat Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and
led to early termination of the study. Results of a planned interim analysis demonstrated that the regimen did not demonstrate sufficient evidence of efficacy necessary to justify further enrollment. Per protocol, the results of this analysis led to early termination of the study. | |||
| NCT03927443 Details | 2021-11-19 Interventional | 3 | 0 | Bimatoprost Glaucoma Glaucoma, Open-… Hypertension Ocular Hyperten… Open Angle Glau… | [Sponsors decision] - | |||
| NCT03071094 Details | 2021-11-19 Interventional | 1/2 | 14 | Nivolumab Carcinoma Carcinoma, Hepa… Hepatocellular … | The decision was taken to stop prematurely the trial due to the failure of Pexa-Vec and
nivolumab in their respective pivotal trials (i.e., PHOCUS and CheckMate 459). The study was terminated prematurely as per Sponsor's decision based on the failure of Pexa-Vec and nivolumab in their respective pivotal trials in HCC. As a consequence, the enrollment in Phase IIa was not completed. | |||
| NCT01420679 2010-022230-81 Details | 2021-11-19 Interventional | 3 | 21 | 10-deazaaminopt… Aminopterin Lymphoma Lymphoma, T-Cel… Lymphoma, T-Cel… Peripheral T-ce… | - The study was prematurely terminated due to business reasons. There were no safety concerns that led to study closure. No efficacy assessments and analysis was conducted. A full statistical analysis and report were not completed. | |||
| NCT04874831 2019-003575-19 Details | 2021-11-18 Interventional | 2 | 0 | Avelumab Carcinoma Carcinoma, Merk… Merkel Cell Car… | Refocusing of sponsor's clinical development program. No safety concern or change of the
risk-benefit assessment of the investigational medicinal product has led to this decision. - | |||
| NCT04497948 Details | 2021-11-17 Interventional | 1 | 9 | Acalabrutinib COVID-19 | Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19
did not meet their primary efficacy endpoints.
Based on this higher management made the decision to prematurely terminate the D822FC00005 PK
study. - | |||
| NCT03712930 2018-002587-28 Details | 2021-11-17 Interventional | 2 | 13 | Pamiparib Prostatic Neopl… Homologous Reco… Metastatic Cast… | Sponsor's decision to revisit the development approach for prostate cancer. - | |||
| NCT02934503 Details | 2021-11-16 Interventional | 2 | 5 | Carboplatin Etoposide Pembrolizumab Lung Neoplasms Small Cell Lung… Small Cell Lung… | This study was terminated as the standard of care for small cell lung cancer changed in 2018 to
include immunotherapy in the front line setting, making this study no longer clinically
relevant. - | |||
| NCT01312389 Details | 2021-11-15 Interventional | 1/2 | 3 | Monatide (IMS 3… poly(I).poly(c1… Fallopian Tube … Peritoneal Neop… Fallopian Tube … Ovarian Cancer Primary Periton… | Did not meet criteria laid out in Phase 1 to continue to Phase 2 - | |||
| NCT03337152 Details | 2021-11-12 Interventional | 4 | 54 | Chloroquine Primaquine Glucosephosphat… Malaria, Vivax G6PD Deficiency | study met study halting rules The study met study halting rules and was terminated early. As a result, the full sample size was not enrolled and a complete data set was not available. Thus, the objectives of assessing and developing a G6PD risk model could not be met. | |||
| NCT00618917 Details | 2021-11-12 Interventional | 1/2 | 18 | Carboplatin Manganese Paclitaxel Superoxide Dism… Lung Neoplasms Esophageal Toxicity | MnSOD longer available during Phase II - |